Literature DB >> 21527338

The biological basis of injury and neuroprotection in the fetal and neonatal brain.

Sandra Rees1, Richard Harding, David Walker.   

Abstract

A compromised intrauterine environment that delivers low levels of oxygen and/or nutrients, or is infected or inflammatory, can result in fetal brain injury, abnormal brain development and in cases of chronic compromise, intrauterine growth restriction. Preterm birth can also be associated with injury to the developing brain and affect the normal trajectory of brain growth. This review will focus on the effects that episodes of perinatal hypoxia (acute, chronic, associated with inflammation or as an antecedent of preterm birth) can have on the developing brain. In animal models of these conditions we have found that relatively brief (acute) periods of fetal hypoxemia can have significant effects on the fetal brain, for example death of susceptible neuronal populations (cerebellum, hippocampus, cortex) and cerebral white matter damage. Chronic placental insufficiency which includes fetal hypoxemia, nutrient restriction and altered endocrine status can result in fetal growth restriction and long-term deficits in neural connectivity in addition to altered postnatal function, for example in the auditory and visual systems. Maternal/fetal inflammation can result in fetal brain damage, particularly but not exclusively in the white matter; injury is more pronounced when associated with fetal hypoxemia. In the baboon, in which the normal trajectory of growth is affected by preterm birth, there is a direct correlation between a higher flux in oxygen saturation and a greater extent of neuropathological damage. Currently, the only established therapy for neonatal encephalopathy in full term neonates is moderate hypothermia although this only offers some protection to moderately but not severely affected brains. There is no accepted therapy for injured preterm brains. Consequently the search for more efficacious treatments continues; we discuss neuroprotective agents (erythropoietin, N-acetyl cysteine, melatonin, creatine, neurosteroids) which we have trialed in appropriate animal models. The possibility of combining hypothermia with such agents or growth factors is now being considered. A deeper understanding of causal pathways in brain injury is essential for the development of efficacious strategies for neuroprotection.
Copyright © 2011 ISDN. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21527338      PMCID: PMC3168707          DOI: 10.1016/j.ijdevneu.2011.04.004

Source DB:  PubMed          Journal:  Int J Dev Neurosci        ISSN: 0736-5748            Impact factor:   2.457


  173 in total

Review 1.  Role of instrumented fetal sheep preparations in defining the pathogenesis of human periventricular white-matter injury.

Authors:  Stephen A Back; Art Riddle; A Roger Hohimer
Journal:  J Child Neurol       Date:  2006-07       Impact factor: 1.987

2.  Combination of systemic hypothermia and N-acetylcysteine attenuates hypoxic-ischemic brain injury in neonatal rats.

Authors:  Manu Jatana; Inderjit Singh; Avtar K Singh; Dorothea Jenkins
Journal:  Pediatr Res       Date:  2006-05       Impact factor: 3.756

3.  Cerebral outcomes in a preterm baboon model of early versus delayed nasal continuous positive airway pressure.

Authors:  Michelle Loeliger; Terrie Inder; Sarah Cain; Rajalakshmi C Ramesh; Emily Camm; Merran A Thomson; Jacqueline Coalson; Sandra M Rees
Journal:  Pediatrics       Date:  2006-10       Impact factor: 7.124

Review 4.  Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants.

Authors:  S M Aher; A Ohlsson
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

Review 5.  Chorioamnionitis: important risk factor or innocent bystander for neonatal outcome?

Authors:  Wolfgang Thomas; Christian P Speer
Journal:  Neonatology       Date:  2010-09-28       Impact factor: 4.035

6.  Chronic exposure to intra-amniotic lipopolysaccharide affects the ovine fetal brain.

Authors:  Ilias Nitsos; Sandra M Rees; Jhodie Duncan; Boris W Kramer; Richard Harding; John P Newnham; Timothy J M Moss
Journal:  J Soc Gynecol Investig       Date:  2006-05

7.  Erythropoietin concentrations and neurodevelopmental outcome in preterm infants.

Authors:  Ryann Bierer; M Connie Peceny; Carol H Hartenberger; Robin K Ohls
Journal:  Pediatrics       Date:  2006-08-14       Impact factor: 7.124

8.  Sex-dependent effect of a low neurosteroid environment and intrauterine growth restriction on foetal guinea pig brain development.

Authors:  Meredith A Kelleher; Hannah K Palliser; David W Walker; Jonathan J Hirst
Journal:  J Endocrinol       Date:  2010-12-13       Impact factor: 4.286

9.  Erythropoietin protects the developing retina in an ovine model of endotoxin-induced retinal injury.

Authors:  Michelle M Loeliger; Anna Mackintosh; Robert De Matteo; Richard Harding; Sandra M Rees
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-04-22       Impact factor: 4.799

10.  Arginine:glycine amidinotransferase (AGAT) deficiency in a newborn: early treatment can prevent phenotypic expression of the disease.

Authors:  Roberta Battini; M Grazia Alessandrì; Vincenzo Leuzzi; Francesca Moro; Michela Tosetti; Maria C Bianchi; Giovanni Cioni
Journal:  J Pediatr       Date:  2006-06       Impact factor: 4.406

View more
  72 in total

1.  Epigenetic regulation of fetal brain development and neurocognitive outcome.

Authors:  Zdravko Petanjek; Ivica Kostović
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-02       Impact factor: 11.205

2.  Effects of Lipopolysaccharide and Progesterone Exposures on Embryonic Cerebral Cortex Development in Mice.

Authors:  Ashlie A Tronnes; Jenna Koschnitzky; Ray Daza; Jane Hitti; Jan Marino Ramirez; Robert Hevner
Journal:  Reprod Sci       Date:  2015-11-30       Impact factor: 3.060

Review 3.  Lactoferrin and prematurity: a promising milk protein?

Authors:  Theresa J Ochoa; Stéphane V Sizonenko
Journal:  Biochem Cell Biol       Date:  2016-10-26       Impact factor: 3.626

Review 4.  Therapeutic potential to reduce brain injury in growth restricted newborns.

Authors:  Julie A Wixey; Kirat K Chand; Lily Pham; Paul B Colditz; S Tracey Bjorkman
Journal:  J Physiol       Date:  2018-05-23       Impact factor: 5.182

5.  Antenatal pharmacokinetics and placental transfer of N-acetylcysteine in chorioamnionitis for fetal neuroprotection.

Authors:  Donald B Wiest; Eugene Chang; Deanna Fanning; Sandra Garner; Toby Cox; Dorothea D Jenkins
Journal:  J Pediatr       Date:  2014-07-23       Impact factor: 4.406

6.  Endogenous erythropoietin varies significantly with inflammation-related proteins in extremely premature newborns.

Authors:  J Wells Logan; Elizabeth N Allred; Raina N Fichorova; Stephen Engelke; Olaf Dammann; Alan Leviton
Journal:  Cytokine       Date:  2014-06-02       Impact factor: 3.861

7.  MR venography of the fetal brain using susceptibility weighted imaging.

Authors:  Jaladhar Neelavalli; Swati Mody; Lami Yeo; Pavan Kumar Jella; Steven J Korzeniewski; Sheena Saleem; Yashwanth Katkuri; Ray O Bahado-Singh; Sonia S Hassan; E Mark Haacke; Roberto Romero; Moriah E Thomason
Journal:  J Magn Reson Imaging       Date:  2013-11-25       Impact factor: 4.813

Review 8.  Music therapy in the NICU: is there evidence to support integration for procedural support?

Authors:  Kimberly A Allen
Journal:  Adv Neonatal Care       Date:  2013-10       Impact factor: 1.968

9.  Abnormal heart rate characteristics are associated with abnormal neuroimaging and outcomes in extremely low birth weight infants.

Authors:  K D Fairchild; R A Sinkin; F Davalian; A E Blackman; J R Swanson; J A Matsumoto; D E Lake; J R Moorman; J A Blackman
Journal:  J Perinatol       Date:  2014-02-20       Impact factor: 2.521

Review 10.  Age, plasticity, and homeostasis in childhood brain disorders.

Authors:  Maureen Dennis; Brenda J Spiegler; Jenifer J Juranek; Erin D Bigler; O Carter Snead; Jack M Fletcher
Journal:  Neurosci Biobehav Rev       Date:  2013-10-03       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.